CA2255121A1 - Compositions d'erythrocytes et procedes permettant de prelever et de stocker les erythrocytes - Google Patents
Compositions d'erythrocytes et procedes permettant de prelever et de stocker les erythrocytes Download PDFInfo
- Publication number
- CA2255121A1 CA2255121A1 CA002255121A CA2255121A CA2255121A1 CA 2255121 A1 CA2255121 A1 CA 2255121A1 CA 002255121 A CA002255121 A CA 002255121A CA 2255121 A CA2255121 A CA 2255121A CA 2255121 A1 CA2255121 A1 CA 2255121A1
- Authority
- CA
- Canada
- Prior art keywords
- red
- anticoagulant
- approximately
- blood
- dextrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims description 34
- 210000004369 blood Anatomy 0.000 claims abstract description 73
- 239000008280 blood Substances 0.000 claims abstract description 73
- 210000004027 cell Anatomy 0.000 claims abstract description 70
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 49
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 49
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 239000008121 dextrose Substances 0.000 claims description 26
- 239000012141 concentrate Substances 0.000 claims description 25
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 22
- 206010018910 Haemolysis Diseases 0.000 claims description 14
- 230000008588 hemolysis Effects 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 239000001509 sodium citrate Substances 0.000 claims description 14
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 12
- 229930024421 Adenine Natural products 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 229960000643 adenine Drugs 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 11
- 229940038773 trisodium citrate Drugs 0.000 claims description 11
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 description 20
- 238000000926 separation method Methods 0.000 description 20
- 239000000306 component Substances 0.000 description 13
- 239000012503 blood component Substances 0.000 description 12
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 10
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 10
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 5
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- XOHUEYCVLUUEJJ-UWTATZPHSA-N 2,3-bisphospho-D-glyceric acid Chemical compound OP(=O)(O)O[C@@H](C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UWTATZPHSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Environmental Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- External Artificial Organs (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des procédés permettant de prélever des érythrocytes, procédés selon lesquels on associe le sang total à un anticoagulant, on sépare les érythrocytes du sang total et on associe les érythrocytes séparés à une solution de stockage. Les érythrocytes peuvent être stockés pendant une longue période de temps.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81910697A | 1997-03-18 | 1997-03-18 | |
| US08/819,106 | 1997-03-18 | ||
| PCT/US1998/003712 WO1998041087A1 (fr) | 1997-03-17 | 1998-02-25 | Compositions d'erythrocytes et procedes permettant de prelever et de stocker les erythrocytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2255121A1 true CA2255121A1 (fr) | 1998-09-24 |
Family
ID=25227212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002255121A Abandoned CA2255121A1 (fr) | 1997-03-17 | 1998-02-25 | Compositions d'erythrocytes et procedes permettant de prelever et de stocker les erythrocytes |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0909128A1 (fr) |
| JP (1) | JP4340927B2 (fr) |
| CA (1) | CA2255121A1 (fr) |
| WO (1) | WO1998041087A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7049110B2 (en) | 1998-07-21 | 2006-05-23 | Gambro, Inc. | Inactivation of West Nile virus and malaria using photosensitizers |
| US7498156B2 (en) | 1998-07-21 | 2009-03-03 | Caridianbct Biotechnologies, Llc | Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components |
| US7220747B2 (en) | 1999-07-20 | 2007-05-22 | Gambro, Inc. | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer |
| EP1455860B1 (fr) | 2001-12-10 | 2011-08-31 | CaridianBCT, Inc. | Procedes de leucoreduction de globules rouges |
| EP1496947A1 (fr) | 2002-04-24 | 2005-01-19 | Gambro, Inc. | Elimination d'adenine au cours d'un procede de reduction des agents pathogenes du sang ou de composants sanguins |
| EP1796457B1 (fr) * | 2004-09-07 | 2011-11-23 | Velico Medical, Inc. | Appareil permettant de prolonger la survie des plaquettes |
| DE602005026043D1 (de) | 2004-10-15 | 2011-03-03 | Velico Medical Inc | Zusammensetzungen und verfahren für die verlängerung der überlebensdauer von blutplättchen |
| US10575515B2 (en) | 2010-05-04 | 2020-03-03 | The General Hospital Corporation | Methods and compositions for preserving tissues and organs |
| CA2826969C (fr) | 2010-11-29 | 2019-02-19 | New York Blood Center, Inc. | Procede de rassemblement et de stockage de sang |
| JP6412696B2 (ja) * | 2014-02-10 | 2018-10-24 | テルモ株式会社 | 血清調製方法および器具 |
| WO2020163774A1 (fr) * | 2019-02-07 | 2020-08-13 | The General Hospital Corporation | Compositions, méthodes et nécessaires pour stabiliser des cellules et des échantillons biologiques |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5248506A (en) * | 1986-03-19 | 1993-09-28 | American National Red Cross | Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets |
-
1998
- 1998-02-25 CA CA002255121A patent/CA2255121A1/fr not_active Abandoned
- 1998-02-25 JP JP54051898A patent/JP4340927B2/ja not_active Expired - Lifetime
- 1998-02-25 EP EP98908724A patent/EP0909128A1/fr not_active Withdrawn
- 1998-02-25 WO PCT/US1998/003712 patent/WO1998041087A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998041087A1 (fr) | 1998-09-24 |
| JP2002522007A (ja) | 2002-07-16 |
| EP0909128A1 (fr) | 1999-04-21 |
| JP4340927B2 (ja) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6527957B1 (en) | Methods for separating, collecting and storing red blood cells | |
| US5899874A (en) | Preparation and method for production of platelet concentrates with significantly prolonged viabilty during storage | |
| US4111199A (en) | Method of collecting transfusable granulocytes by gravity leukopheresis | |
| US9943077B2 (en) | Methods for storing red blood cell products | |
| JP4712135B2 (ja) | 濃縮赤血球の調製における抗凝固及び保存用溶液 | |
| AU2004311906A1 (en) | Processing systems and methods for providing leukocyte-reduced blood components conditioned for pathogen inactivation | |
| EP0447399A1 (fr) | Procede et recipient servant a la preparation et au stockage de concentres de plaquettes | |
| WO1996029864A1 (fr) | Methode de rajeunissement de globules rouges perimes | |
| JP4340927B2 (ja) | 赤血球組成物、および赤血球を収集しそして保存するための方法 | |
| Heath et al. | Treatment of antidepressant poisoning with resin hemoperfusion | |
| Valbonesi et al. | Erythrothrombocytapheresis and plasmathrombocytapheresis with storage in T-sol of platelets collected by the new Amicus cell separator | |
| US20220125043A1 (en) | Methods and systems for processing biological fluids | |
| Hallett Jr | Minimizing the use of homologous blood products during repair of abdominal aortic aneurysms | |
| Högman et al. | A simple method for the preparation of microaggregate‐poor whole blood | |
| EP2777727B1 (fr) | Procédés et systèmes de traitement de fluides biologiques | |
| Brickley et al. | A comparison of two methods of post-bypass hemoconcentration | |
| Valbonesi et al. | Intraoperative blood salvage: a new trend in blood transfusion medicine | |
| Heaton | The quality of red blood cells | |
| Wagner et al. | Processing of bone marrow with the CS‐3000 Plus using the small volume collection chamber. | |
| RU2734121C1 (ru) | Способ трансплантации аутологичных гемопоэтических стволовых клеток периферической крови | |
| Anderson et al. | Bone marrow processing on the Haemonetics V50 cell separator | |
| Bruni et al. | New options for multicomponent collection (MCC) with the latest cell separators | |
| Walpoth et al. | Blood salvage in cardiac surgery: Comparative analysis of three different procedures | |
| Gonzalez-Campos et al. | Bone marrow processing using the fenwal CS-3000 plus blood cell separator: results of 99 procedures | |
| Muylle et al. | Separation of buffy coat using the top and bottom drainage system: reduction of red blood cell loss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |